Business

Novartis to acquire Synnovation Therapeutics PI3Kα inhibitor program for up to USD 3b.

Novartis has agreed to acquire Pikavation Therapeutics, a wholly-owned subsidiary of Synnovation Therapeutics, to gain control of SNV4818 and related PI3Kα inhibitor programs. The Novartis Synnovation acquisition, announced on March 19, 2026, covers a pan-mutant selective PI3K alpha small molecule inhibitor currently in Phase 1/2 trials for HR+/HER2- metastatic breast cancer and other solid tumors. Synnovation is a clinical-stage company headquartered in Wilmington, Delaware, focused on small-molecule targeted therapies in oncology and immunology.

Under the agreement, Novartis will pay Synnovation USD 2 billion in upfront cash and up to USD 1 billion in development, regulatory, and commercial milestone payments, for total potential consideration of up to USD 3 billion. No royalties, profit-sharing arrangements, or equity components were disclosed. The upfront payment represents approximately 67% of the total deal value. The transaction is expected to close in H1 2026, subject to antitrust review under the Hart-Scott-Rodino Act. Novartis will assume sole responsibility for all future development and commercialization of the acquired programs.

Deal context

SNV4818 is a small molecule designed to selectively inhibit multiple oncogenic mutations of PI3Kα while sparing the wild-type enzyme. PIK3CA mutations encoding PI3Kα are among the most common oncogenic alterations in HR+/HER2- breast cancer and occur across other solid tumor types. First-generation PI3Kα inhibitors, including Novartis's own alpelisib, inhibit both mutant and wild-type forms of the enzyme. This lack of mutant selectivity drives on-target toxicities including hyperglycemia, rash, and diarrhea. Pan-mutant selective inhibitors aim to widen the therapeutic window by concentrating activity on the disease-driving mutant protein. A Phase 1/2 trial evaluating SNV4818 as monotherapy and in combination with fulvestrant or palbociclib in patients with advanced PIK3CA-mutant solid tumors is ongoing, with enrollment of 320 participants across sites in Canada and Australia (NCT06736704). No clinical data from this trial have been publicly reported.

The AllSci BriefSystematic R&D and deal news. Daily.

For Novartis, this deal represents an effort to defend and extend its position in the PI3Kα pathway. Alpelisib generated the company's initial franchise in PIK3CA-mutant breast cancer but faces displacement by agents with improved tolerability profiles. Acquiring SNV4818 allows Novartis to develop a next-generation successor using its existing breast cancer commercial infrastructure. Synnovation retains its remaining pipeline, including SNV1521, a PARP1-selective inhibitor in Phase 1, along with additional oncology and immunology programs.

The PI3Kα inhibitor landscape has become competitive. Several companies are developing next-generation mutant-selective agents targeting the same biology.

  • Tersolisib (STX-478) — Eli Lilly (acquired from Scorpion Therapeutics) — Phase 3 pivotal trial; allosteric, pan-mutant selective, CNS-penetrant
  • Zovegalisib (RLY-2608) — Relay Therapeutics — Phase 1/2, with Phase 3 planned; allosteric, pan-mutant and isoform-selective
  • OKI-219 — OnKure Therapeutics — Phase 1; mutation-specific (H1047R only)
  • LY4045004 — Eli Lilly (internal) — preclinical/early clinical; pan-mutant selective
  • Inavolisib (Itovebi) — Roche/Genentech — approved 2024; PI3Kα-selective but not mutant-selective

Lilly's tersolisib is the most advanced next-generation program and has already entered a front-line pivotal study. Relay's zovegalisib showed consistent efficacy and tolerability in updated data presented at ASCO 2025. Lilly's earlier mutation-specific candidate LOXO-783 was discontinued after showing limited monotherapy activity in Phase 1, which has shifted competitive consensus toward pan-mutant approaches. SNV4818 enters this field behind at least two competitors with more advanced clinical data, though Novartis's existing commercial presence in PI3Kα-mutant breast cancer and its global development capabilities could accelerate the program's path through later-stage trials.


Spot something wrong? Report an issue with this article